H. Yin

First name
H.
Last name
Yin
Shapiro, S. B., Yin, H., H. Y. Yu, O., & Azoulay, L. (2024). Dipeptidyl Peptidase-4 Inhibitors and the Risk of Gallbladder and Bile Duct Disease Among Patients with Type 2 Diabetes: A Population-Based Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-024-01434-4
View
Simms-Williams, N., Treves, N., Yin, H., Lu, S., Yu, O., Pradhan, R., et al. (2024). Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. Bmj, 385, e078242. http://doi.org/10.1136/bmj-2023-078242
View
Shapiro, S. B., Yin, H., H. Y. Yu, O., & Azoulay, L. (2024). Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.16039
View
Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., et al. (2023). Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15196
View
Abrahami, D., Pradhan, R., Yin, H., Yanofsky, R., McDonald, E. G., Bitton, A., & Azoulay, L. (2023). Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study. Gut. http://doi.org/10.1136/gutjnl-2022-328866
View
Pradhan, R., Lu, S., Yin, H., H. Y. Yu, O., Ernst, P., Suissa, S., & Azoulay, L. (2022). Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. Bmj, 379, e071380. http://doi.org/10.1136/bmj-2022-071380
View
Suissa, K., Schneeweiss, S., Douros, A., Yin, H., Patorno, E., & Azoulay, L. (2022). Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Diabetes Res Clin Pract, 192, 110094. http://doi.org/10.1016/j.diabres.2022.110094
View
Abrahami, D., Tesfaye, H., Yin, H., Vine, S., Hicks, B., H. Y. Yu, O., et al. (2022). Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care. http://doi.org/10.2337/dc22-1174
View
Pradhan, R., Yin, H., H. Y. Yu, O., & Azoulay, L. (2022). Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc22-0712
View
Lu, S., Yin, H., H. Y. Yu, O., & Azoulay, L. (2022). Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients with Type 2 Diabetes. Epidemiology. http://doi.org/10.1097/ede.0000000000001486
View